Organoids are simple tissue engineered in vitro models that closely mimics the physiological conditions of complex in vivo native tissue. Organoids bridge the gap between two-dimensional (2D) cell line culture and in vivo models. Organoids recapitulate organ development and human diseases such as infectious diseases, genetic abnormalities, tumor microenvironments etc. Organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Organoids developed using patient’s tissue recapitulate the patient physiology and disease phenotype, such as genetic profiles, drug sensitivities etc. These models are used to improve preclinical drug discovery, clinical trial validation and ultimately patient care. Cancer is a heterogenous disease in terms of stage, genetic background, molecular behaviour etc, requiring personalised treatment. This webinar will explore the transformative potential of these advanced models in accelerating drug development, improving disease understanding and enhancing precision medicine approaches. Participant will learn about how stem cell derived organoids are used to mimic human diseases like cancer, neurodegenerative diseases, metabolic diseases etc. we will also discuss the advantage of organoid technology over animal models and other conventional 2D models.

 Key Highlights of the Webinar:

• Introduction to organoids and their role in bridging the gap between traditional cell culture and in vivo models.
• Applications of organoids in drug discovery, disease modeling, and personalized medicine.
• Insights into how patient-derived organoids are used to mimic human diseases like cancer, neurodegenerative, and metabolic disorders.
• The advantages of organoid technology over animal models and conventional 2D models.